1621 - Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 fluorescence in situ hybridisation testing to identify ROS1, to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme

Page last updated: 27 February 2020

Application Detail

Description of Medical Service

The proposed service is testing of the ROS1 gene rearrangement by fluorescence in situ hybridisation (FISH) to determine eligibility to access entrectinib under the PBS.

This submission requests a minor amendment to MBS item 73344 be made allowing its use to determine eligibility to access crizotinib or entrectinib under the PBS.

Description of Medical Condition

Non-small cell lung cancer.

Reason for Application

Amendment to MBS item

Medical Service Type

Investigative

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

-

Consultation Survey

-

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

N/A

ESC

N/A

MSAC

2-3 April 2020.